Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Marc J. Fishman
Friends Research Institute, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mountain Manor Treatment Cente
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Fishman has an executive position and board membership with equity interest and salary in Mountain Manor Treatment Centers (MMTC), the clinic from which study participants will be recruited. The Friends Research Institute’s (FRI) Institutional Review Board had noted this conflict in a letter date August 22, 2012 to Dr. Shannon G. Mitchell, the Principal Investigator of the study. The value of Dr. Fishman’s interest in MMTC exceeds the $5,000 FCOI threshold. Study participants must be enrolled at MMTC. Given Dr. Fishman’s equity interest in MMTC, he stands to profit from their participation in the study.
Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth
The proposed study is significant because opioid-dependent youth are at risk of continuing drug use, overdose death, HIV and hepatitis infection, and illegal behavior. Current treatments are only partially successful and leave room for improvement. The proposed study of extended release naltrexone will improve treatment outcomes for this population. The proposed study is innovative because it will provide novel data comparing treatment effectiveness of extended release naltrexone to treatment-as-usual and it will provide novel cost data as well. The public health impact of the proposed study will be high because the study may reveal that this new approach to treatment can reduce or prevent illicit drug use, HIV risk behavior, crime, and overdose compared to treatment-as-usual care.
Filed on May 15, 2013.
Tell us what you know about Marc J. Fishman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.